West Nile Virus Consultative Workshop Programme

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

Contact : CERB/CBE

CROWNE PLAZA HOTEL
OTTAWA, ONTARIO

JANUARY 9, 2003

Organizing Committee

Dr. Peter Ganz
Ms. Cristina Pecora
Mr. Peter Neumann
Dr. Farid Hindieh
Dr. Agnes Klein

OCAPI Facilitators

Ms. Fern Levine, Co-ordinator
Ms. Caroline Vaughn
Ms. Susan Tessier
Ms. Heather McGregor
Ms. Michelle Reimer
Dr. Basanti Ghosh
Ms. Charlotte Tremblay

Workshop Planning

Dr. Peter Ganz
Ms. Cristina Pecora
Ms. Julia Hill

Administration

Ms. Cristina Pecora
Ms. Judy Corbishley
Ms. Pauline Fournier
Ms. Francine Latremouille
Ms. Jeannine Vanker

Programme

Time:	Agenda:	Organization/Speaker
Session I	Managing West Nile Virus Risk - Chaired by: Ms. Julia Hill
8:00 a.m. - 8:10 a.m.	Welcome and Introduction	Ms. Diane Gorman Ms. Julia Hill
8:10 a.m. - 8:30 a.m.	WNV Safety & Regulatory Overview Canada	Dr. Peter Ganz (HC)
8:30 a.m. - 9:00 a.m.	WNV and Safety of the US Blood Supply	Dr. H. Nakhasi (FDA)
9:00 a.m. - 9:30 a.m.	WNV and Transfusion/ Transplantation Risk	Dr. M. Chamberland (CDC)
9:30 a.m.- 9:45 am	Questions and Answers Session
9:45 a.m. - 10:00 a.m.	BREAK

Question #5

What areas of WNV research need focused attention?

Participants

Dr. A. Mortimer
Dr. D. Sutherland
Dr. P. Buck
Dr. E. Farzad
Mr. E. Morrier
Dr. A. Doty
Dr. P. Webber
Dr. S. Roberecki
Dr. K. Grimsrud
Dr. A. Corriveau
Dr. G. Rock
Ms. J. Hamilton
Dr. E. Charbonneau
Mr. I. Mumford
Dr. R. Lemieux
Dr. M. St-Louis
Dr. H. Nakhasi
Dr. W. Graham
Ms. S. Poirier

Rapporteurs:

Dr. H. Artsob & Dr. W. Casley

Facilitator:

Ms. H. McGregor

Time:	Agenda:	Organization/Speaker
Session II	West Nile Virus Testing - Chaired by: Dr. Robert Peterson
10:00 a.m. - 10:20 a.m.	WNV Surveillance and Testing - Canada	Dr. M. Drebot (PPHB)
10:20 a.m. - 10:40 am	WNV Testing Development - Update	Dr. James Gallarda Roche Diagnostics
10:40 a.m. - 11:00 a.m.	West Nile Virus Update	Dr. J. Linnen (Gen-Probe)
11:00 a.m. - 11:20 a.m.	Pathogen Inactivation Technology and West Nile Virus	Baxter Co. (TBA)
11:20 a.m. - 11:45 am	Questions and Answers Session
11:45 am - 12:30 pm	LUNCH BREAK
Session III	West Nile Virus Operations Perspective Chaired by: Dr. Bill Casley
12:30 pm - 12:50	CBS's Response to WNV as a threat to the Blood Supply	Dr. E.Vamvakas (CBS)
12:50 pm - 1:10 pm	Héma-Québec and West Nile Virus	Dr. Gilles Delage (HQ)

Question #4

What measures should be considered to reduce risk if tests for WNV are not available?

Participants

Dr. R. Peterson
Dr. A. Dudani
Mr. E. Ouimette
Ms. K. Farrell
Dr. C. Costello
Ms. N. Fauchir
Ms. H. Gagne
Dr. H. Arruda
Dr. C. D'Cunha
Dr. R. Findlater
Mr. V. Scalia
Mr. A. Roch
Mr. W. Rees
Ms. S. Thibault
Dr. P. Chan
Mr. W. Busch
Dr. M. Chamberland
Mr. B. Mindell
Ms. J. Vilk
Dr. L. Nicolle

Rapporteurs:

Dr. P. Sockett & Dr. W. Stevens

Facilitator:

Mr. R. Leitch

Time:	Agenda:	Organization/Speaker
Session IV	Discussion and Recommendations - Chaired by: Dr. A. Klein
1:30 pm - 1:40	Introduction to Facilitated Sessions - OCAPI and TPD	Ms. F. Levine
1:40 pm - 3:00	Breakout Sessions	OCAPI Facilitators
3:00 pm - 3:15 pm	BREAK
3:15 pm - 4:00	Breakout Sessions - continued
4:00 pm - 4:50	Summaries and Discussion of Breakout Sessions
4:50 pm 5:00	Closing Remarks & Adjournment	Dr. P. Ganz (BGTD)

Question #3

What processes can be put in place to facilitate development of testing for WNV?

Participants

Dr. K. Nyarko
Dr. M. Drebot
Mr. D. Boyer
Dr. C. Legare
Dr. J. Linnen
Dr. J. Gallarda
Dr. M. Baikie
Dr. C. Balram
Dr. M.Kjerulf
Dr. H. Hume
Dr. F. Decary
Ms. S. Remy-Prince
Mr. B. Kane
Dr. K. Kovacs Burnes
Ms. L. French
Ms. J. Sirna
Mr. E. Chabot

Rapporteurs:

Ms. Maria Carballo & Dr. Lindsay Elmgren

Facilitators:

Ms. Michelle Reimer (Dr. Basanti Ghosh)

Question #2

What strategies should be considered to reduce risk of WNV transmission through transfusion or transplantation? Pros and Cons considered for each strategy?

Participants

Dr. Roland Rotter
Dr. S. Sharma
Dr. H. Njoo
Mr. J. Lambert
Dr. E. Griffiths
Ms. J. Koch
Dr. R. Vadehra
Ms. T. Chong-King
Dr. F. Stratton
Dr. L. Sweet
Dr. I. Gemmill
Dr. E. Vamvakas
Dr. M. Germain
Dr. P. Dubord
Dr. J. Teitel
Dr. D. Wong-Rieger
Ms. S. Comerford
Dr. L. Petersen
Ms. D. Tremblay
Ms. M. Hand
Dr. T. Bowen

Rapporteurs:

Mr. P. Neumann and Dr. F. Hindieh

Facilitator:

Ms. S. Tessier

Question #1

What are the key messages to be communicated to the public about WNV risk? About transfusion and transplantation risks?

Participants

Dr. A. Klein
Ms. B. Benning
Ms. R. Dansereau
Dr. S. El Saadany
Dr. L. Stringfellow
Mr. B. Labossiere Bees
Mr. P. Chapman
Dr. B. Larke
Dr. M. Fyfe
Dr. L. Heubsch
Dr. G. Sher
Dr. G. Delage
Dr. B. Singh
Dr. J. Freedman
Mr. G. Dafoe
Ms. E. Chatigny
Mr. M. Fruitman
Mr. R. Legault
Ms. L. Stevens
Mr. D. Page

Rapporteurs:

Dr. A. Giulivi & Mr. K. Moore

Facilitator:

Ms. C. Vaughn

Questions for Breakout Sessions

1. What are the key messages to be communicated to the public about WNV risk? About transfusion and transplantation risks? Rapporteurs : Dr Antonio Giulivi et Mr. Ken Moore
2. What strategies should be considered to reduce risk of WNV transmission through transfusion or transplantation? Pros and Cons considered for each strategy. Rapporteurs : M. Peter Neumann et Dr Farid Hindieh
3. What processes can be put in place to facilitate development of testing for WNV. Rapporteurs : Mme Maria Carballo et Dr Lindsay Elmgren
4. What measures should be considered to reduce risk if tests for WNV are not available? Rapporteurs: Dr Paul Sockett et Dr Will Stevens
5. What areas of WNV research need focused attention? Rapporteurs : Dr Harvey Artsob et Dr Bill Casley